Chronic lymphocytic leukaemia (CLL; small lymphocytic lymphoma, SLL)
Lymphoproliferative · Haematology / Oncology
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Commonest adult leukaemia: clonal mature B-lymphocyte accumulation. Often incidental lymphocytosis; may present with lymphadenopathy, splenomegaly, cytopenias, recurrent infection, autoimmune haemolysis/ITP, or B symptoms. ED role: recognise, treat complications (infection, autoimmune cytopenias, Richter transformation), avoid tumour lysis on starting therapy, refer.
Red flags
- Febrile neutropenia / sepsis in immunocompromised host
- Rapid nodal enlargement + B symptoms + high LDH (Richter transformation to aggressive lymphoma)
- Autoimmune haemolysis / severe ITP
- Bulky nodes causing compression (airway, ureteric, cord)
- Tumour lysis on commencing venetoclax
Assessment
Differential diagnosis
- Reactive lymphocytosis (viral, pertussis)
- Other lymphoproliferative disorders (mantle cell, marginal zone, prolymphocytic leukaemia, hairy cell)
- Monoclonal B-cell lymphocytosis (<5 x10^9/L clonal B cells, no disease)
- Non-Hodgkin lymphoma with leukaemic phase
Investigations
- FBC + film (mature lymphocytosis >=5 x10^9/L B cells, smudge/smear cells)
- Peripheral blood immunophenotyping/flow cytometry (CD5+, CD19+, CD23+, weak sIg) - diagnostic, marrow usually not needed
- DAT/Coombs, reticulocytes, LDH, haptoglobin (autoimmune haemolysis), platelet count (ITP)
- Immunoglobulins (hypogammaglobulinaemia), U&E, urate
- CT / prognostic markers (TP53/del(17p), IGHV) before treatment per haematology
- If rapid nodal growth/B symptoms: consider Richter transformation - biopsy +/- PET
Management
- Confirm diagnosis by flow cytometry; stage (Binet/Rai)
- Asymptomatic early-stage disease: 'watch and wait' - treatment does not improve survival
- Treat if: progressive/symptomatic cytopenias, bulky/symptomatic nodes or spleen, B symptoms, doubling lymphocyte count, autoimmune cytopenias uncontrolled
- Manage infections aggressively (treat as immunocompromised); consider Ig replacement for recurrent infection + hypogammaglobulinaemia
- Autoimmune haemolysis/ITP: corticosteroids first-line (as for AIHA/ITP)
- On starting cytoreductive therapy with high burden: tumour lysis prophylaxis (hydration, allopurinol/rasburicase)
- Suspect Richter transformation if sudden deterioration/rapid nodal enlargement/high LDH - urgent biopsy
Drugs & doses
Targeted therapy is now standard first-line (haematology-directed): BTK inhibitors - ibrutinib / acalabrutinib / zanubrutinib, or BCL-2 inhibitor venetoclax + obinutuzumab [verify local dose]
Venetoclax - strict ramp-up dosing with tumour lysis prophylaxis (start 20 mg, weekly escalation to 400 mg) [verify local dose]
Prednisolone 1 mg/kg/day PO for autoimmune haemolysis/ITP complications [verify local dose]
Allopurinol 300 mg PO once daily +/- rasburicase for tumour lysis prophylaxis when treating high tumour burden [verify local dose]
Immunoglobulin replacement for recurrent infection with hypogammaglobulinaemia [verify local dose]
Aciclovir / PCP prophylaxis per regimen; vaccinate (avoid live vaccines)
Disposition
Infection/autoimmune cytopenia/suspected transformation/TLS -> admit with haematology. Stable incidental lymphocytosis -> outpatient haematology referral.
Complications & pitfalls
- Recurrent/opportunistic infection (major cause of death)
- Autoimmune haemolytic anaemia / ITP / pure red cell aplasia
- Richter transformation (to DLBCL/Hodgkin)
- Tumour lysis syndrome with venetoclax
- Secondary malignancy
Exam pearls
- Flow cytometry on peripheral blood usually diagnoses CLL - marrow often unnecessary
- Early asymptomatic CLL: watch and wait; early treatment does not prolong life
- Smudge cells on film are a classic clue
- Venetoclax requires meticulous dose ramp-up and tumour lysis prophylaxis - high tumour burden can cause fatal TLS
- Sudden clinical deterioration with rising LDH = think Richter transformation, biopsy urgently
- Test for del(17p)/TP53 before treatment - chemoimmunotherapy avoided; use targeted agents
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.